Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Breast 3Genitourinary 2Plasma cell 1Other hematologic neoplasm 1Head & Neck 1CNS 1

Conditions

Breast Neoplasms 2046Triple Negative Breast Neoplasms 208Neoplasm Metastasis 133Neoplasms 119Carcinoma, Non-Small-Cell Lung 96Breast Neoplasms, Male 95Ovarian Neoplasms 89Colorectal Neoplasms 70Lung Neoplasms 67Carcinoma, Intraductal, Noninfiltrating 63Melanoma 57Prostatic Neoplasms 55Pancreatic Neoplasms 47Breast Carcinoma In Situ 42Stomach Neoplasms 38Colonic Neoplasms 37Brain Neoplasms 36Carcinoma, Renal Cell 35Inflammatory Breast Neoplasms 33Head and Neck Neoplasms 32Urinary Bladder Neoplasms 29Pain 29Small Cell Lung Carcinoma 27Squamous Cell Carcinoma of Head and Neck 26Endometrial Neoplasms 25Sarcoma 23Fatigue 23Uterine Cervical Neoplasms 21Esophageal Neoplasms 21Multiple Myeloma 18

Interventions

Zoledronic Acid 2saracatinib 1odanacatib 1Vitamin D 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Bone Diseases × Breast × Clear all
NCT00399802 2018-08-16

A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 2 Completed
43 enrolled 10 charts
Breast

Bone Diseases, Breast Neoplasms

NCT00904423 2017-02-14

Ph I/II of Vitamin D on Bone Mineral Density & Markers of Bone Resorption

Stanford University

Phase 1/2 Terminated
8 enrolled 4 charts
Breast

Bone Diseases, Breast Neoplasms

NCT00558272 2013-05-27

Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease

AstraZeneca

Phase 2 Completed
139 enrolled 23 charts
BreastGenitourinarySarcoma

Bone Diseases, Bone Neoplasms, Breast Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡